Zydus

Candidate Targets Indication Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
PRS-110 cMet Oncology Major Markets
Discovery Phase completed
Pre-Clinical Phase in progress
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started

In October 2013, Pieris initiated a collaboration with Zydus Cadila for the development and commercialization of novel Anticalin®-based protein therapeutics. Zydus will be responsible for IND-enabling studies, GMP manufacturing and clinical development in certain emerging markets, while Pieris will maintain rights for the co-developed compounds in key major markets. The lead program under this collaboration is an Anticalin protein against cMet for multiple Oncology indications.